Navigation Links
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Date:1/31/2013

MADISON, Wis., Jan. 31, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Novelos and its collaborators is being made by Dr. Christopher Pazoles at the EMIT: Targeted Radiotherapy international conference taking place January 29 to 31, in Washington, D.C.  This presentation by invitation from EMIT describes the mechanistic foundation for Novelos' diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged accumulation of Novelos' PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types.  Dr. Pazoles is the Senior Vice President of Research and Development for Novelos.

"LIGHT, HOT and GLOW2 were designed to exploit a feature shared by most, if not all, cancer cells including cancer stem cells, which results in the selective uptake and prolonged accumulation of our proprietary, small-molecule delivery vehicle in a wide range of malignant tumors compared with normal tissues," said Dr. Pazoles.  "By incorporating a unique functional property in each – PET imaging, radiotherapy or optical imaging – we have generated an array of potential therapeutic and diagnostic products that could, alone or in combinations, significantly improve the detection and treatment of cancer in multiple ways."

Slides of the presentation are available at www.novelos.com/technology-ip/posters-publications/

In his presentation, titled Cancer-Targeted Diapeutics: Radioiodinated Phospholipid Ether Analogs for Broad-Spectrum Imag
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Today Eli Lilly and Company (NYSE: LLY ... to increase the global supply of medicines for multidrug-resistant ... donating manufacturing technology and know-how for two antibiotics to ... India , Russia ... MDR-TB ,hot spots., It also served as the foundation ...
(Date:10/27/2014)... Research and Markets has announced the addition of ... their offering. H1N1 influenza (zoonotic) is an ... swine H1N1 virus, known as H1N1v virus. The H1N1v virus ... H1N1 virus is an RNA virus belonging to the Orthomyxoviridae ... humans, swine, birds, seals, and horses. Influenza A viruses can ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... , LAKE FOREST, Ill. , Jan. 12 ... of injectable pharmaceuticals announced today the launch of Ibutilide ... from Pfizer Inc. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , ... Pharma,s continued growth and dedication to a consistently expanding ...
... Jan. 12 CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of approximately 15%, to 8.75 cents per share on ... holders of record on January 22, 2010 . This increase translates into ... cents per share from the previous rate of 30.5 cents . ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2CVS Caremark Corporation Increases Quarterly Dividend 15% 2
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
(Date:10/30/2014)... TX (PRWEB) October 30, 2014 ... released today its 2014 third quarter infection rates ... Texas boasted infection rates of only two percent ... patient satisfaction scores exceeding 98 percent. , “We ... quarter, which included rising satisfaction scores,” said Robert ...
(Date:10/30/2014)... When it comes to heart disease, a new study finds ... they have symptoms that spell trouble. "The main danger ... more severe or advanced stage of heart disease, there are ... Fulbright Scholar and research fellow at the Harvard School of ... and Stroke Foundation of Canada. In the study, researchers ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 ... pregnancy may have effects on genital development in baby boys, ... born to moms with greater exposure to a chemical called ... space between the genitals and anus. Anogenital distance is set ... to androgens ("male" hormones) during pregnancy. The researchers said ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Many U.S. ... campus, even though tanning increases the risk for ... among young adults, particularly white women, so colleges ... health, the researchers said. "Public health efforts ... population awareness of the harms that indoor tanning ...
Breaking Medicine News(10 mins):Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... examines the use of tissue-engineered scaffolding made of cartilage cells, ... defective cartilage tissue. ,Cartilage cells are extracted ... body, where new cartilage tissue is grown along the structure. ... ,The procedure was extremely successful in tested mice as the ...
... between the immune systems of humans and opossums, the ... lead to breakthroughs in the understanding and treatment of ... found only in the Australian island state of Tasmania. ... full set of genetic information of the South American ...
... as to why oral cancer has been on the rise ... candidates . American scientists say that oral sex is a ... HPV between partners and may give cause to oral cancer ... any substance known to predispose to the disease. ...
... A new study reveals that almost two-thirds of ... their life, but very few of them experience ... certain emotional resilience in children, but it also suggests ... from adults, said William Copeland of Duke University Medical ...
... A new vaccine aimed at preventing cervical cancer is nearly ... papillomavirus (HPV) responsible for most cases of cervical cancer. ... published in the May 10 issue of the New England ... of young women, a series of three shots of a ...
... Research Hospital had a molecules eye view of the ... a double-strand break to link together the broken ... the twisted, ladder-like structure of DNA, breaking it into ... for this project, the St. Jude researchers could determine ...
Cached Medicine News:Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Swallowing The Bitter Pill-Oral Sex Linked To Oral Cancer 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2Health News:DNA Repair Proteins Monitored at Double-strand Break 2
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... Excilite- is a portable, compact, lightweight ... capable of emitting the same intensity (50 ... on a smaller treatment area (30 cm). ... order to satisfy the most demanding professional ...
... system used in neurophysiology for studying evoked potentials. ... and/or the duration of the stimulus as well ... emission in an ongoing manner by acting on ... include the high repeatability of the impulses, the ...
... 1.0 is a high power pulsed ... response to pain, even in the ... differs from the other laser devices ... full safety, all the 3 laser ...
Medicine Products: